Moriya Y, Hojo K, Sawada T, Makuuchi M, Yamasaki S, Hasegawa H
Dep. of Surgery, National Cancer Center Hospital.
Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-2):1331-6.
During the past 13 years, 125 patients with liver metastasis from colorectal cancer underwent hepatic resection. Among these patients, 90 received potentially curative hepatectomy except for twelve patients who received curative hepatectomy combined with hepatic arterial infusion therapy and 23 patients who received non-curative surgery. The results of surgical treatment, and modes of recurrence following hepatectomy were studied in these 90 patients. The overall 5-year survival rate was 38.6%. Recurrent tumor developed in 59 patients, 42 being found in the remnant liver (47%), 15 in the lung (17%) and 8 at the primary site. The survival rate of the 43 patients who received systemic chemotherapy after hepatectomy was similar to that of the 24 patients who received no chemotherapy. According to this analysis, we have designed a chemotherapy protocol involving infusion through hepatic artery using on Infusaid port, to prevent regrowth in the remnant liver and pulmonary metastasis. In our program, MMC 10mg and 5-FU 750 to 1,000 mg/body were given through the Infusaid port, and HCFU 400 mg orally. Although the follow-up period has been short, no regrowth in the remnant liver has developed in 12 patients who received this treatment.